Zelboraf and Weight increased - a phase IV clinical study of FDA data

Summary:

Weight increased is reported as a side effect among people who take Zelboraf (vemurafenib), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Actemra, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Weight increased when taking Zelboraf. It is created by eHealthMe based on reports of 8,381 people who have side effects when taking Zelboraf from the FDA, and is updated regularly.

What is Zelboraf?

Zelboraf has active ingredients of vemurafenib. eHealthMe is studying from 8,392 Zelboraf users. Check the latest studies of Zelboraf.

What is Weight increased?

Weight increased is found to be associated with 2,909 drugs and 3,893 conditions by eHealthMe. Check the latest studies of Weight increased.

On Nov, 06, 2025

8,381 people reported to have side effects when taking Zelboraf.
Among them, 24 people (0.29%) have Weight increased.

Among these 24 people:

How long have people been on Zelboraf when they have Weight increased? *

What is the gender of people who have Weight increased when taking Zelboraf? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Weight increased when taking Zelboraf? *

What are other drugs people take besides Zelboraf? *

What are other side effects people have besides Weight increased? *

Nausea And Vomiting: 9 people, 37.50%
Diarrhea: 8 people, 33.33%
Fatigue (feeling of tiredness): 8 people, 33.33%
Fever: 8 people, 33.33%
High Blood Pressure: 7 people, 29.17%
Weight Decreased: 6 people, 25.00%
Speech Impairment (Adult) (inability to speak (adult)): 6 people, 25.00%
Rashes (redness): 6 people, 25.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 20.83%
Blood Pressure Diastolic Decreased: 5 people, 20.83%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 8 people, 33.33%
Erdheim-Chester Disease (abnormal multiplication of a specific type of white blood cells): 6 people, 25.00%
Urinary Tract Infection: 5 people, 20.83%
Malignant Melanoma (skin cancer rises from melancytes): 5 people, 20.83%
Pain: 4 people, 16.67%
High Blood Pressure: 3 people, 12.50%
Stress And Anxiety: 2 people, 8.33%
Bone Disorder: 1 person, 4.17%
Brain Neoplasm Malignant (brain cancer tumour): 1 person, 4.17%
Brain Stem Glioma (cancerous glioma tumour in the brainstem): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Zelboraf and have Weight increased?

- Check whether Weight increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zelboraf:

Zelboraf (8,392 reports)

Weight increased treatments and more:

Weight increased (279,364 reports)

Browse all side effects of Zelboraf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight increased:

Weight increased (2,909 drugs)

Browse all the conditions that are associated with Weight increased:

Weight increased (3,893 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vemurafenib (the active ingredients of Zelboraf) and Zelboraf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.